Moreover, we reported that patients with a higher CD169+ cell number or higher CD169+/CD68+ macrophage ratio in RLNs had a better clinical prognosis than those with lower levels of CD169+ cells in those cancers [18, 21]. The gene discussed is SIGLEC1; the disease is cancer.